Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Root

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Cardiovascular Translational Research|June 19, 2010
Implantable cardiac rhythm device batteriesMichael J Root
The Journal of Biological Chemistry|July 12, 2017
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitorsKoree W Ahn, Michael J Root
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|December 13, 2002
Clinical pharmacology of human growth hormone and its secretagoguesAllen W Root, Michael J Root
The Journal of Biological Chemistry|June 29, 2006
Kinetic dependence to HIV-1 entry inhibitionH Kirby Steger, Michael J Root
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2003
Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion proteinMichael J Root, Dean H Hamer
Current Pharmaceutical Design|June 8, 2004
HIV-1 gp41 as a target for viral entry inhibitionMichael J Root, H Kirby Steger
The Journal of Biological Chemistry|December 17, 2008
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coilKelly Champagne, Akira Shishido, Michael J Root
Biomacromolecules|March 30, 2012
Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitorsMaarten Danial, Michael J Root, Harm-Anton Klok
The Journal of Investigative Dermatology|January 27, 2007
C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cellsMakoto Sugaya, Oliver Hartley, Michael J Root, et al.
Plos Pathogens|December 4, 2009
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingKristen M Kahle, H Kirby Steger, Michael J Root
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Cardiovascular Translational Research|June 19, 2010
Implantable cardiac rhythm device batteriesMichael J Root
The Journal of Biological Chemistry|July 12, 2017
Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitorsKoree W Ahn, Michael J Root
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|December 13, 2002
Clinical pharmacology of human growth hormone and its secretagoguesAllen W Root, Michael J Root
The Journal of Biological Chemistry|June 29, 2006
Kinetic dependence to HIV-1 entry inhibitionH Kirby Steger, Michael J Root
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2003
Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion proteinMichael J Root, Dean H Hamer
Current Pharmaceutical Design|June 8, 2004
HIV-1 gp41 as a target for viral entry inhibitionMichael J Root, H Kirby Steger
The Journal of Biological Chemistry|December 17, 2008
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coilKelly Champagne, Akira Shishido, Michael J Root
Biomacromolecules|March 30, 2012
Polyvalent side chain peptide-synthetic polymer conjugates as HIV-1 entry inhibitorsMaarten Danial, Michael J Root, Harm-Anton Klok
The Journal of Investigative Dermatology|January 27, 2007
C34, a membrane fusion inhibitor, blocks HIV infection of langerhans cells and viral transmission to T cellsMakoto Sugaya, Oliver Hartley, Michael J Root, et al.
Plos Pathogens|December 4, 2009
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingKristen M Kahle, H Kirby Steger, Michael J Root
Pageof 3